Infantile hemangioma (IH) is the most common vascular tumor of infancy, affecting as many as 5% to 10% of all infants. The exact cause is unclear, but specific risk factors, such as low birth weight, prematurity, female sex, white race, and family history are associated with IH development. Most IHs are benign and self-resolving, but a small subset of patients with IHs are at risk of severe or life-threatening outcomes. Systemic and topical β-blockers are effective and safe for use in pediatric patients and considered first-line treatment for both complicated and uncomplicated IHs. Recently published guidelines provide a thorough review of IH and management. This article focuses on IH pharmacotherapy and provides practice pearls to support health care providers in IH medication management.
Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls
- Views Icon Views
- Share Icon Share
- Search Site
Laura Tiemann, Sarrah Hein; Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls. The Journal of Pediatric Pharmacology and Therapeutics 1 September 2020; 25 (7): 586–599. doi: https://doi.org/10.5863/1551-6776-25.7.586
Download citation file: